NX-5948

Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). BTK-IN-24 (NX-5948; compound 195) is a potent BTK inhibitor via a ubiquitin proteolytic pathway.


Cat. No.: EX-A7961	Purity: 98+%

	Chemical structure of NX-5948

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	532	In-stock
250mg	850	In-stock
500mg	1296	In-stock
1g	2048	In-stock
3g	3850	In-stock
5g	5556	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Bexobrutideg
Synonyms 2	BTK-IN-24
CAS No.	2649400-34-8
Purity	98+%
Formula	C42H54N12O5
Mol Weight	806.9556
Color	off-white to yellow
State	solid powder
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Mark Noviski, et al. NX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease. 2021 Nurix Therapeutics, Inc. [2]. 4473 Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies. Annual Meeting & Exposition, Monday, December 11, 2023. [3]. Zi Liu, et al. An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed. 2022 Dec 20;3(1):46. [4]. Eyre, Toby A, and John C Riches. “The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.” Cancers vol. 15,9 2596. 3 May. 2023 [5]. Sands, et al. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway. World Intellectual Property Organization, WO2021113557 A1. 2021-06-10.
Data Sheet	Data sheet of NX-5948
CoA	CoA of NX-5948
SDS	SDS of NX-5948


		Search